CRISPR-mediated KLRC1 gene editing not only targets the NKG2A/HLA-E IC but also enhances NK cell cytotoxic responses against HLA-E-positive tumor cells by augmenting NKG2C function [49]. The gene discussed is KLRC1; the disease is neoplasm.